DR. DANIEL E BAUER, MD, PHD
Medical Practice at Longwood Ave, Boston, MA
License number
Massachusetts 237913
Category
Medical Practice
Type
Pediatric Hematology-Oncology
Address
Address
300 Longwood Ave, Boston, MA 02115
Phone
(617) 355-7701
Personal information
See more information about DANIEL E BAUER at radaris.comName
Address
Phone
570 Marrett Rd, Lexington, MA 02421
Professional information
Dr. Daniel E Bauer, Boston MA - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Age:
47
Address:
450 Brookline Ave, Boston 02215
IMMUNOLOGY DV
300 Longwood Ave, Boston 02115
(617) 919-2484 (Phone), (617) 730-0528 (Fax)
CHILDRENS HOSPITAL BOSTON
300 Longwood Ave, Boston 02115
(617) 355-6117 (Phone), (617) 738-7066 (Fax)
IMMUNOLOGY DV
300 Longwood Ave, Boston 02115
(617) 919-2484 (Phone), (617) 730-0528 (Fax)
CHILDRENS HOSPITAL BOSTON
300 Longwood Ave, Boston 02115
(617) 355-6117 (Phone), (617) 738-7066 (Fax)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2013, Pediatrics, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Univ Of Pa Sch Of Med
Graduated: 2003
Univ Of Pa Sch Of Med
Graduated: 2003
Daniel E Bauer, Boston MA
Specialties:
Pediatric Hematologist / Oncologist
Address:
300 Longwood Ave, Boston, MA 02115
Daniel E Bauer, Boston MA
Specialties:
Pediatrics, Pediatric Hematology-Oncology, Hematology & Oncology
Work:
Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215
450 Brookline Ave, Boston, MA 02215
Education:
University of Pennsylvania(2006)
Regulation Of Autophagy And Cell Survival
US Patent:
2008026, Oct 30, 2008
Filed:
Jan 19, 2006
Appl. No.:
11/814365
Inventors:
Craig B. Thompson - Merion PA, US
Julian Lum - Philadelphia PA, US
Daniel Bauer - Boston MA, US
Julian Lum - Philadelphia PA, US
Daniel Bauer - Boston MA, US
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - Philadelphia PA
International Classification:
A61K 31/52, A61K 31/47, C12Q 1/02, A61P 35/00
US Classification:
5142634, 514313, 435 29
Abstract:
Methods of treating an individual who has been identified as having glycolysis dependent cancer are disclosed. The methods comprise the step of: administering to such an individual a combination of an anti-cancer composition that renders the cancer incapable of glycolysis and an autophagy inhibitor. Pharmaceutical compositions and kits comprising that renders the cancer incapable of glycolysis and an autophagy inhibit are also disclosed. Methods of treating an individual who has a disease characterized b cell degeneration and cell death due to autophagy are disclosed. The methods comprise administering to the individual a permeable form of a metabolic substrate that can be oxidized in the tricarboxylic acid cycle to produce NADH. Methods for identifying an autophagy inhibitor comprising performing a test assay using an apopto sis-resistant cell are disclosed.